A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF SECUKINUMAB (AIN457) TO EXAMINE THE CLINICAL EFFICACY AND THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)-SPARING EFFECT OF SECUKINUMAB OVER 16 WEEKS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: